HEAT Trial (HER2 Antibody Therapy With Lutetium-177)

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 12, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions

HER2 Gene MutationAdvanced Solid Tumors

Interventions

DRUG

177Lu-RAD202

177Lu-RAD202 administered at Imaging (im) and Treatment (tr) doses

Trial Locations (2)

RECRUITING

Nepean Hospital, Kingswood

RECRUITING

GenesisCare Murdoch, Murdoch

All Listed Sponsors

lead

Radiopharm Theranostics, Ltd

INDUSTRY